Theriva Biologics Files 8-K Report
Ticker: TOVX · Form: 8-K · Filed: Oct 20, 2025 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, company-update
TL;DR
Theriva Biologics filed an 8-K, likely containing financial updates or other key company news.
AI Summary
On October 20, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing indicates that the company, formerly known as Synthetic Biologics, Inc., ADEONA PHARMACEUTICALS, INC., and PIPEX PHARMACEUTICALS, INC., is reporting "Other Events" and "Financial Statements and Exhibits." No specific financial details or significant events were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that Theriva Biologics is making a regulatory submission to the SEC, which could contain important updates for investors regarding financial status or other material events.
Risk Assessment
Risk Level: low — The filing is a standard procedural report without immediate disclosed material changes or financial distress.
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- Synthetic Biologics, Inc. (company) — Former Company Name
- ADEONA PHARMACEUTICALS, INC. (company) — Former Company Name
- PIPEX PHARMACEUTICALS, INC. (company) — Former Company Name
- October 20, 2025 (date) — Date of Report
FAQ
What specific "Other Events" are being reported by Theriva Biologics in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" being reported; it only lists the item category.
What are the key details within the "Financial Statements and Exhibits" section of this filing?
The excerpt does not provide specific details from the "Financial Statements and Exhibits" section, only that it is included in the filing.
When was Theriva Biologics, Inc. incorporated, and in which jurisdiction?
Theriva Biologics, Inc. was incorporated in Nevada.
What is the IRS Employer Identification Number (EIN) for Theriva Biologics, Inc.?
The IRS Employer Identification Number (EIN) for Theriva Biologics, Inc. is 13-3808303.
What is the business address of Theriva Biologics, Inc. as listed in the filing?
The business address is 9605 Medical Center Drive, Suite 270, Rockville, MD 20850.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-10-20 07:22:41
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica
Filing Documents
- tm2529071d1_8k.htm (8-K) — 25KB
- tm2529071d1_ex99-1.htm (EX-99.1) — 20KB
- tm2529071d1_ex99-1img001.jpg (GRAPHIC) — 196KB
- tm2529071d1_ex99-1img002.jpg (GRAPHIC) — 107KB
- tm2529071d1_ex99-1img003.jpg (GRAPHIC) — 255KB
- tm2529071d1_ex99-1img004.jpg (GRAPHIC) — 200KB
- tm2529071d1_ex99-1img005.jpg (GRAPHIC) — 228KB
- tm2529071d1_ex99-1img006.jpg (GRAPHIC) — 167KB
- tm2529071d1_ex99-1img007.jpg (GRAPHIC) — 182KB
- tm2529071d1_ex99-1img008.jpg (GRAPHIC) — 123KB
- tm2529071d1_ex99-1img009.jpg (GRAPHIC) — 170KB
- tm2529071d1_ex99-1img010.jpg (GRAPHIC) — 152KB
- tm2529071d1_ex99-1img011.jpg (GRAPHIC) — 160KB
- tm2529071d1_ex99-1img012.jpg (GRAPHIC) — 150KB
- tm2529071d1_ex99-1img013.jpg (GRAPHIC) — 214KB
- tm2529071d1_ex99-1img014.jpg (GRAPHIC) — 161KB
- tm2529071d1_ex99-1img015.jpg (GRAPHIC) — 37KB
- 0001104659-25-100608.txt ( ) — 3649KB
- syn-20251020.xsd (EX-101.SCH) — 3KB
- syn-20251020_lab.xml (EX-101.LAB) — 33KB
- syn-20251020_pre.xml (EX-101.PRE) — 22KB
- tm2529071d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On October 20, 2025, expanded metastatic pancreatic ductal adenocarcinoma (mPDAC) data from Theriva Biologics, Inc.'s VIRAGE Phase 2b trial (NCT05673811) was presented at a mini oral session at the European Society for Medical Oncology (ESMO 2025) Annual Congress The ESMO presentation is atatched as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 ESMO presentation 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 20, 2025 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer